A Registrational Trial Investigating CK-301 as First-Line Treatment in Patients with Non-Small Cell Lung Cancer

Trial Profile

A Registrational Trial Investigating CK-301 as First-Line Treatment in Patients with Non-Small Cell Lung Cancer

Planning
Phase of Trial: Phase II/III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs CK 301 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Checkpoint Therapeutics
  • Most Recent Events

    • 27 Mar 2018 New trial record
    • 21 Mar 2018 According to Checkpoint Therapeutics media release, company is expecting to initiat this trial in the first quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top